Follow-up of effectiveness in patients with inflammatory bowel diseases treated by ustekinumab and vedolizumab
Not Applicable
- Conditions
- ulcerative colitis and Crohn's disease
- Registration Number
- JPRN-UMIN000039947
- Lead Sponsor
- Saitama Medical Center, Saitama Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with severe infection 2. Patients with active tuberculosis 3. Patients who has allergy against ustekinumab and vedolizumab 4. Maternal patients and patients with breastfeeding 5. Patients who has malignancy and who has past history of malignancy 6. Patients who has ostomy 7. Patients determined to be inappropriate for this study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Persistence of ustekinumab and vedolizumab at week 56
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie ustekinumab and vedolizumab efficacy in IBD?
How do ustekinumab and vedolizumab compare to standard-of-care therapies for Crohn's disease and ulcerative colitis?
Which biomarkers predict response to ustekinumab and vedolizumab in IBD patients?
What are the known adverse events associated with ustekinumab and vedolizumab in IBD treatment?
Are there combination therapies involving ustekinumab and vedolizumab showing improved outcomes in IBD?